glioblastoma

Attendees heard about the past and future of the Cancer Genome Atlas at the American Association for Cancer Research meeting in Denver this week, as the pilot stage of the project nears completion.

The new budget and stimulus funds will fuel the Genome Atlas, a personalized medicine platform, and more grants to young investigators.

The company will use the hospital's cancer clinical and genetic data to develop technologies for glioblastoma diagnostics or treatments.

The company also plans to begin a series of non-human primate studies to test its delivery technology, a move that is largely driven by the demands of potential big pharma partners for better data before forming alliances.

Genomics vs. Cancer

Premium

Recent advances in the battle against cancer have come from sequencing, microRNAs, barcode arrays, disease stratification, pathway analysis, and more.

Snippets

Premium

Alzheimer's Disease Neuroimaging Initiative, OncoMethylome Sciences, Merck KGaA, 23andMe, Michael J. Fox Foundation for Parkinson's Research, Parkinson's Institute and Clinical Center, and more …

The Belgian firm is providing gene methylation testing services for two glioblastoma drug trials.

Both the project and the service are designed to offer cancer patients detailed information about their tumor at a timescale that can help their physicians tailor treatments. However, some experts say the results will not benefit many patients today.

Complete Genomics will use its DNA sequencing technology to sequence five samples provided by the Broad Institute.

Short Reads

Premium

Febit, Complete Genomics, Broad Institute, EnGenCore, German Genetics Society, Albert Einstein College of Medicine, CLC Bio, Boehringer Ingelheim, Genomatix

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.